

Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

1. Identifying information.

2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party — that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Definitions.

Entity: government agency, foundation, commercial sponsor, academic institution, etc.

Grant: A grant from an entity, generally [but not always] paid to your organization

Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

Pending: The patent has been filed but not issued **Issued:** The patent has been issued by the agency

Licensed: The patent has been licensed to an entity, whether earning royalties or not

Royalties: Funds are coming in to you or your institution due to your patent



Section 1. Identifying Inform	nation				
1. Given Name (First Name) Corey	2. Surname (Last N Siegel	Name)		3. Date 17-January-2017	
4. Are you the corresponding author?	✓ Yes No				
5. Manuscript Title 2016-2017_ECCO_Annual_Disclosure					
6. Manuscript Identifying Number (if you kr	now it)				
Section 2. The Work Under C	onsideration for	Publication			
Did you or your institution at any time rece any aspect of the submitted work (including statistical analysis, etc.)? Are there any relevant conflicts of intere	g but not limited to g				tc.) for
Section 3. Relevant financial	activities outsid	e the submitted	work.		
Place a check in the appropriate boxes of compensation) with entities as descr clicking the "Add +" box. You should re Are there any relevant conflicts of interesting of the second of	ibed in the instruct port relationships t est?	ions. Use one line f	or each entity;	add as many lines as you nee	ed by
Name of Entity	Grant? Person	_	Other? Co	omments	
CCFA	✓				
AHRQ(1R01HS021747)	✓				
AbbVie	V			nt support, Speaker for CME vities, Consultant	
Janssen	/			nt Support, Speaker for CME vities, Consultant	
Takeda	V		Acti	nt Support, Speaker for CME vities, Consultant	
UCB	✓		Gran	nt Support, Consultant	



Salix Amgen Consultant Theradiag Consultant Consultant Consultant Consultant Consultant Theradiag Consultant Consul	mgen		ant	ersonal ees?	Non-Financial Support?	Other?	Comm	ents
Consultant Prometheus Consultant Licensed Consultant Consultant Consultant Consultant Consultant Consultant Consultant Licensed Consultant Consultant Consultant Consultant Consultant Licensed Consultant Consultant Consultant Licensed Consultant Consultant Consultant Consultant Licensed Consultant Consultant Consultant Licensed Consultant Consultant Consultant Licensed Consultant Consultant Licensed Consultant Consultant Licensed Consultant Consultant Licensed Consultant Licensed Consultant Licensed Consultant Consultant Licensed Consultant Licensed Consultant Licensed Consultant Licensed Consultant Licensed Consultant Consultant Consultant Licensed Consultant Licensed Consultant Licensed Consultant Licensed Consultant			√	✓			Grant Sup	oport, Consultant
Prometheus Consultant Licensee? One Medical Center and Cedars-Sinai	1157			✓			Consultar	nt
Consultant Cheradiag Consultant Consult	шу			✓			Consultar	nt
Section 4. Intellectual Property Patents & Copyrights Do you have any patents, whether planned, pending or issued, broadly relevant to the work? Yes No If yes, please fill out the appropriate information below. If you have more than one entity press the "ADD" button to add a rexcess rows can be removed by pressing the "X" button. Patent? Pending? Issued? Licensed? Royalties? Licensee? Comments Posternand Method of Communicating Predicted Medical Outcomes Dartmouth—Hitchcock Medical Center and Cedars-Sinai Discontinuous Consultant Consultant Consultant Double Patent Double Patent Dartmouth—Hitchcock Medical Center and Cedars-Sinai Discontinuous Consultant Consultant Double Patent Double Patent Dartmouth—Hitchcock Medical Center and Cedars-Sinai	izer			✓			Consultar	nt
Section 4. Intellectual Property Patents & Copyrights Do you have any patents, whether planned, pending or issued, broadly relevant to the work? Yes No If yes, please fill out the appropriate information below. If you have more than one entity press the "ADD" button to add a rexcess rows can be removed by pressing the "X" button. Patent? Pending? Issued? Licensed? Royalties? Licensee? Comments Dartmouth-Hitchcock Medical Center and Cedars-Sinai Dartmouth-Hitchcock Medical Center and Cedars-Sinai	ometheus			✓			Consultar	nt
Do you have any patents, whether planned, pending or issued, broadly relevant to the work? Yes No If yes, please fill out the appropriate information below. If you have more than one entity press the "ADD" button to add a rexcess rows can be removed by pressing the "X" button. Patent? Pending? Issued? Licensed? Royalties? Licensee? Comments ystem and Method of Communicating Predicted Medical Center and Cedars-Sinai	neradiag			✓			Consultar	nt
Do you have any patents, whether planned, pending or issued, broadly relevant to the work? Yes No If yes, please fill out the appropriate information below. If you have more than one entity press the "ADD" button to add a rexcess rows can be removed by pressing the "X" button. Patent? Pending? Issued? Licensed? Royalties? Licensee? Comments System and Method of Communicating Predicted Medical Dutcomes Dartmouth-Hitchcock Medical Center and Cedars-Sinai	ristol-Meyers Squibb			✓			Consultar	nt
ystem and Method of ommunicating Predicted Medical utcomes Dartmouth-Hitchcock Medical Center and Cedars-Sinai Dartmouth-Hitchcock Medical Center and Cedars-Sinai	Excess rows can be removed b	by pressing the	"X" butt	on.				
Communicating Predicted Medical Dutcomes Hitchcock Medical Center and Cedars-Sinai								
Medical Center	ommunicating Predicted Medical	✓				Hitchcock Center and	Medical S d ai	



Section 6.

Disclosure Statement

Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.

Dr. Siegel reports grants from CCFA, grants from AHRQ(1R01HS021747), grants and personal fees from AbbVie, grants from Janssen, grants from Takeda, grants from UCB, grants and personal fees from Salix, personal fees from Amgen, personal fees from Lilly, personal fees from Prometheus, personal fees from Theradiag, personal fees from Bristol-Meyers Squibb, outside the submitted work; In addition, Dr. Siegel has a patent System and Method of Communicating Predicted Medical Outcomes pending to Dartmouth-Hitchcock Medical Center and Cedars-Sinai Medical Center.

Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.